Siltuximab
As of the edition of 20 October 2026, Siltuximab is an antibody: marketed, first approved in 2014 (US); acts on IL6; US protection ended in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Antibody
- Brand name
- Sylvant
- First approved
- 23 April 2014 (US)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- Recordati Rare Diseases; 2 holders in all
- Registered trials
- 39, 9 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Urinary and reproductive; Infections
US protection
US protection ended in 2026.
US protection ended in 2026, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Recordati Rare Diseases. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Siltuximab.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL6 | Interleukin-6 | P05231 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 12 | 6 | 2 | 3 |
| Phase 2 | 23 | 13 | 6 | 4 |
| Phase 3 | 3 | 0 | 1 | 2 |
| All trials | 39 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Recordati | Applicant | 2014 to now |
| Recordati Rare Diseases | Acquired holder | 2024 to now |